...
首页> 外文期刊>Journal of women’s health >Ovarian function preservation by GnRH agonists during chemotherapy.
【24h】

Ovarian function preservation by GnRH agonists during chemotherapy.

机译:在化疗期间,GnRH激动剂可保持卵巢功能。

获取原文
获取原文并翻译 | 示例
           

摘要

Ihave read with great interest the recent meta-analysis by Clowse et al.; the authors are congratulated for their fine review. There is, however, a small mistake in reporting the results of Waxman et al. This study, from 1987, found that 4 of the 8 patients in the GnRH agonists (GnRHa) group suffered Premature Ovarian Failure (POF) (50.0%) vs. 6 of the 9 patients in the control group (66.7%), not as erroneously reported by Clowse et al.: "6/9 of the controls preserved ovarian function." This may change the final results in the same direction as the authors found, and may even strengthen their conclusion. Also, in the last few months, two prospective randomized controlled (RCT) studies have found a statistically significant advantage of GnRHa cotreatment in preserving ovarian function. The first of these two peer-reviewed RCTs, found 11.4% POF in the GnRHa group vs. 66% POF in controls (p < 0.001). Similarly, the second RCT concluded that: "Among women treated with goserelin, there was a statistically significant increase in the proportion of menstruating women," and "...protective effect of goserelin on ovarian function in CMF treated women."
机译:我非常感兴趣地阅读了Clowse等人最近的荟萃分析;感谢作者的出色评论。但是,在报告Waxman等人的结果时有一个小错误。这项始于1987年的研究发现,GnRH激动剂(GnRHa)组的8位患者中有4位发生了卵巢早衰(POF)(50.0%),而对照组的9位患者中有6位(66.7%)没有发生卵巢早衰。 Clowse等人错误地报告:“ 6/9的对照保留了卵巢功能。”这可能会改变最终结果的方向与作者发现的方向相同,甚至可能会加强他们的结论。另外,在最近几个月中,两项前瞻性随机对照(RCT)研究发现GnRHa协同治疗在保持卵巢功能方面具有统计学上的显着优势。在这两个同行评审的RCT中,第一个发现GnRHa组的POF为11.4%,而对照组的POF为66%(p <0.001)。同样,第二项RCT得出的结论是:“在接受戈舍瑞林治疗的妇女中,经期妇女的比例有统计学上的显着增加”,以及“ ...戈塞瑞林对CMF治疗妇女的卵巢功能的保护作用。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号